HERCULES, Calif., April 18 /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. , a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that it has filed a Schedule 13D statement of ownership with the U. S. Securities and Exchange Commission in which it disclosed its ownership of approximately 6.8% of BioSource International Inc. . In an April 6 announcement, Bio-Rad reported that it held close to 5% of BioSource's outstanding shares and offered to purchase all remaining shares for $8.50 per share.
"Our purchase of additional shares in BioSource further demonstrates our continuing interest in acquiring this company. Including these recent stock purchases, the average price for the shares we have acquired to date is still well below our $8.50 per share offer," said Bio-Rad President Norman Schwartz. "We have noted with interest that BioSource's board is actively considering the sale of BioSource and welcome the opportunity to meet with company officials and their newly appointed advisors to discuss ways to move swiftly toward an agreement that is in the interest of all shareholders."
Bio-Rad Laboratories, Inc. (http://www.bio-rad.com/) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.
Various statements made within this press release may constitute "forward- looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward- looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations.
Bio-Rad Laboratories, Inc.
CONTACT: Ron Hutton, Treasurer of Bio-Rad Laboratories, Inc.,+1-510-741-6142, or email@example.com